Howard W. Robin - May 17, 2021 Form 4 Insider Report for NEKTAR THERAPEUTICS (NKTR)

Role: President & CEO, Director
Signature: Mark A. Wilson, Attorney-in-Fact
Stock symbol: NKTR
Transactions as of: May 17, 2021
Transactions value $: -$211,548
Form type: 4
Date filed: 5/19/2021, 07:05 PM
Next filing: Aug 18, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	NKTR	Common Stock	Sale	-$212K	-11.6K	-2.58%	$18.30^*	436K	May 17, 2021	Direct	F1, F2
holding	NKTR	Common Stock						410	May 17, 2021	by spouse

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2	This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.

Content

Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

This transaction was executed in multiple trades at prices ranging from $17.95 to $18.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the issuer, or a security holder of the issuer.